Company news

Travere Therapeutics, Inc. news in 2023

Travere Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

December 13, 2023

Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS

December 3, 2023

Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

November 20, 2023

Travere Therapeutics Reports Third Quarter 2023 Financial Results

November 6, 2023

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

November 2, 2023

Travere Therapeutics to Report Third Quarter 2023 Financial Results

October 23, 2023

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

October 12, 2023

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2023

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

September 25, 2023

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

September 20, 2023

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 10, 2023

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

September 4, 2023

Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference

August 30, 2023

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

August 23, 2023

Travere Therapeutics Reports Second Quarter 2023 Financial Results

August 2, 2023

Travere Therapeutics to Report Second Quarter 2023 Financial Results

July 19, 2023

Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals

July 16, 2023

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023

June 7, 2023

Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria

May 30, 2023

Travere Therapeutics Reports First Quarter 2023 Financial Results

May 3, 2023

Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

April 30, 2023

Travere Therapeutics to Report First Quarter 2023 Financial Results

April 25, 2023

Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

March 31, 2023

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023

March 22, 2023

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023

March 13, 2023

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

March 2, 2023

Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

February 27, 2023

Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

February 16, 2023

Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

February 15, 2023

Travere Therapeutics Provides Corporate Update and 2023 Outlook

January 8, 2023

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Calls in 2023

Decks in 2023